Your browser doesn't support javascript.
loading
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Sasaki, Koji; Jabbour, Elias J; Ravandi, Farhad; Short, Nicholas J; Thomas, Deborah A; Garcia-Manero, Guillermo; Daver, Naval G; Kadia, Tapan M; Konopleva, Marina Y; Jain, Nitin; Issa, Ghayas C; Jeanis, Vicki; Moore, Haim G; Garris, Rebecca S; Pemmaraju, Naveen; Cortes, Jorge E; O'Brien, Susan M; Kantarjian, Hagop M.
Afiliação
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour EJ; Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Thomas DA; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva MY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jeanis V; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Moore HG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garris RS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • O'Brien SM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian HM; Clinical Science, Chao Family Comprehensive Cancer Center, University of California at Irvine, Orange, California.
Cancer ; 122(23): 3650-3656, 2016 Dec 01.
Article em En | MEDLINE | ID: mdl-27479888
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomo Filadélfia / Protocolos de Quimioterapia Combinada Antineoplásica / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomo Filadélfia / Protocolos de Quimioterapia Combinada Antineoplásica / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2016 Tipo de documento: Article